Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Whither oral tolerance

At the beginning of the year, AutoImmune Inc. investors looked forward to several milestones to give proof that oral tolerance therapy would bring drugs to market for both multiple sclerosis and rheumatoid arthritis. However, AIMM last week reported a "positive trend" but not significant results for two Phase II trials of Colloral chicken collagen for RA, news which followed disappointing Phase III results last month for Myloral bovine myelin for MS (see BioCentury Extra April 22, 1997).

After the Myloral results, AIMM (Lexington, Mass.) said that it planned to conserve its resources and push Colloral forward.

Read the full 953 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE